Company profile

Rgene Corporation

Privately held: no public share price (Privately held; ABVC BioPharma (Nasdaq: ABVC) holds only a minority stake (up to 6.4%), Rgene has no independent listing. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.globenewswire.com/news-release/2022/06/21/2466166/0/en/ABVC-BioPharma-Expands-Co-Development-Partnership-With-Rgene-Corporation.html]) · United States

Assets

(1 total)

1Total Assets

0Approved

0Phase 3 / Filed

1Phase 1–2 / Early

1Diseases

Showing 1 of 1 assets

		Target & Modality
BLEX 404	Phase 2	Innate immune pattern-recognition receptors engaged by beta-glucanSmall molecule	Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.